Groupe Bruxelles Lambert SAAnalysis

Groupe Bruxelles Lambert is a Belgian investment company listed on Euronext Brussels, a member of the BEL20, with more than seventy years of continuous listing behind it. Its net asset value, that is the value of what it owns once debt is deducted, stands at EUR 13,079m at 30 June 2026, or EUR 100.77 a share on 129,800,000 shares. The portfolio itself, EUR 12,231m, falls into three pockets: EUR 6,556m of listed assets, or 54%, EUR 4,679m of directly held private companies, or 38%, and EUR 950m of assets declared non-strategic, or 8%, a pocket being wound down.

The stated doctrine is one of a long horizon: create value over time with the support of a stable family shareholder base, combining growth in net asset value per share, a sustainable dividend and share buybacks. The portfolio, however, has moved a great deal. The company publishes its own register of disposals: adidas for EUR 1.7bn in 2024; the non-strategic pocket for EUR 1.7bn, SGS for EUR 0.8bn and Umicore for EUR 0.3bn in 2025; Umicore again for EUR 0.3bn, Concentrix for EUR 0.1bn and various non-strategic classes for EUR 0.2bn in the first half of 2026. That is EUR 5.1bn in total, recalculated, the company announcing more than five billion without setting out the sum. Against that, EUR 2.3bn committed in a single half-year across three control or joint-control transactions: Rayner, closed on 28 May 2026, BUKO Group, closed on 8 July 2026, and a cash offer on Recordati announced on 22 May 2026 with CVC.

Read together, those two flows say the same thing. GBL sells liquid listed assets and buys private companies it controls. This is not a marginal reallocation, it is a change of trade: from minority shareholder in large listed companies to operator of private ones. The clearest evidence is the non-strategic pocket, declared in run-off since the fourth quarter of 2025 and down 43% in the first half of 2026 alone. A second measure confirms it: the private healthcare pocket, Affidea, Sanoptis and Rayner, moves from 25.42% to 31.22% of the portfolio between 31 December 2025 and 30 June 2026, recalculated, on a portfolio that itself shrank by 4.2%. The numerator rises while the denominator falls: the concentration is deliberate, not suffered.

What is not known must be said too. GBL publishes no average holding period. Both extremes are documented: more than seventy years of continuous listing and a long historical presence in Europe's large listed names on one side; on the other, a Concentrix line entered and sold within the same half-year, and an Umicore position wound down in two steps between November 2025 and February 2026. Calling this house patient because it uses the words long term would be taking an intention for a measurement. On the shareholder side, EUR 773m was returned in cash over the half-year, between a dividend raised to EUR 5.125 a share for 2025 and share buybacks, with nil net debt and EUR 4.6bn of available liquidity. Those buybacks have a consequence the release does not draw: they tighten control. Pargesa's stake moved from 34.2% to 35.1% of the capital without Pargesa buying a single share.